EP Patent

EP4107279A4 — METHODS OF TREATING PSMA-EXPRESSING CANCERS

Assigned to Endocyte Inc · Expires 2024-07-17 · 2y expired

What this patent protects

Patent listed against lutetium-lu-177-vipivotide-tetraxetan.

Drugs covered by this patent

lutetium-lu-177-vipivotide-tetraxetan (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN)

Patent Metadata

Patent number: EP4107279A4
Jurisdiction: EP
Classification: —
Expires: 2024-07-17
Drug substance claim: No
Drug product claim: No
Assignee: Endocyte Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.